The Joint Corp. Common Stock (JYNT)

FairStock Score: 48/100 — MIXED

Key Financials

Strengths

• Generates $6 million in annual free cash flow (5.1% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Conservative balance sheet with debt-to-equity of just 0.13, providing financial flexibility
• Revenue growth of 139.6% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($1) with negative 493% margin of safety—limited downside protection
• Altman Z-Score of 1.7 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

The Joint Corp. Common Stock is a micro-cap healthcare company valued at $125 million. The business generates $57 million in annual revenue with a 1.7% net margin and $6 million in free cash flow. From a quality standpoint, The shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of 1.7 warrants caution. On valuation, the stock is commanding a steep 96.9x multiple, with trades far above its Graham Number ($1) with no margin of safety. Growth dynamics show revenue growing at 139.6% and profit growth of 136.5%. Our composite FairStock Score of 48/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

The's 140% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $6 million in annual free cash flow (5.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 97x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer